Overview

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
To assess the safety and tolerability of single subcutaneous (SC) and intravenous (IV) doses of AMG 181 in healthy subjects and of a single SC dose in subjects with mild to moderate ulcerative colitis (UC)
Phase:
Phase 1
Details
Lead Sponsor:
Amgen